| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-NH-PEG2-CH2COOH does not have a biological target; it is a chemical linker for bioconjugation. The Fmoc group protects the amine during synthesis. The terminal carboxylic acid enables coupling to amine-containing molecules. The hydrophilic PEG2 spacer increases solubility in aqueous media and provides flexibility to conjugated molecules.
|
|---|---|
| ln Vitro |
An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC. Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system.
In vitro activity is not applicable as this is a chemical linker. It is a cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Its utility lies in its chemical reactivity and the properties it imparts to conjugated molecules. |
| ln Vivo |
In vivo activity is not applicable as this is a chemical linker used for in vitro synthesis. It is not a therapeutic agent. Its applications are in the chemical synthesis of ADCs and other bioconjugates. The PEG2 spacer provides moderate hydrophilicity and flexibility.
|
| Enzyme Assay |
For non-cellular assays, Fmoc-NH-PEG2-CH2COOH is used in chemical conjugation reactions. The carboxylic acid group is activated with coupling reagents to form amide bonds with amines. The Fmoc group is removed with piperidine for subsequent reactions. Reaction progress is monitored by analytical techniques. The compound serves as a building block for PEGylated biomolecules.
|
| Cell Assay |
In vitro cellular assays are not applicable as this compound is a chemical linker. It may be used to synthesize ADCs that are later tested in cellular assays, but the linker itself does not have direct cellular activity. Its PEG2 spacer contributes to the solubility of the final conjugate.
|
| Animal Protocol |
In vivo animal experiments are not applicable as this compound is a chemical linker. It is used in the synthesis of ADCs that may be tested in animal models. The PEG2 spacer influences the pharmacokinetic properties of the final conjugate.
|
| ADME/Pharmacokinetics |
Fmoc-NH-PEG2-CH2COOH has a molecular weight of 385.41 and a molecular formula of C₂₁H₂₃NO₆. Purity is ≥98%. The compound is a solid at room temperature with a melting point of 96-100°C. It is typically stored at -20°C and is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Fmoc-NH-PEG2-CH2COOH is a chemical reagent and is not intended for therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. Specific toxicity data are limited as it is a research-grade chemical. Appropriate personal protective equipment should be used.
|
| References | |
| Additional Infomation |
Fmoc-NH-PEG2-CH2COOH is a PEG linker used in ADC development, peptide synthesis, and bioconjugation applications. The Fmoc group provides orthogonal protection for the amine. The PEG2 spacer enhances aqueous solubility and provides flexibility. The compound is also known as Fmoc-AEEA-OH and is widely used in solid-phase peptide synthesis. It is available from various commercial suppliers.
|
| Molecular Formula |
C21H23NO6
|
|---|---|
| Molecular Weight |
385.41042
|
| Exact Mass |
385.152
|
| CAS # |
166108-71-0
|
| PubChem CID |
2756092
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
631.4±45.0 °C at 760 mmHg
|
| Melting Point |
90-92℃
|
| Flash Point |
335.6±28.7 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.580
|
| LogP |
2.63
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
28
|
| Complexity |
491
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XQPYRJIMPDBGRW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H23NO6/c23-20(24)14-27-12-11-26-10-9-22-21(25)28-13-19-17-7-3-1-5-15(17)16-6-2-4-8-18(16)19/h1-8,19H,9-14H2,(H,22,25)(H,23,24)
|
| Chemical Name |
2-[2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~64.87 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5946 mL | 12.9732 mL | 25.9464 mL | |
| 5 mM | 0.5189 mL | 2.5946 mL | 5.1893 mL | |
| 10 mM | 0.2595 mL | 1.2973 mL | 2.5946 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
